LAUSR

To the Editors: W e read with great interest an article in your journal about the evaluation of COVID-19–associated myocarditis. As far as we know, COVID-19 is an infectious disease characterized by respiratory symptoms that can affect multiple organs throughout the body. Because of its own characteristics, myocardial cells are easily attacked and infected by viruses. It is clear that myocardial injury poses not only a huge challenge to the management of COVID-19 but also a greater burden for patients. Therefore, it is also important to distinguishCOVID-19myocarditis from other types of myocarditis as early as possible for the diagnosis and treatment of the disease. Heparin has beenwidely used in clinic for its traditional anticoagulant effect. However, recent studies have elucidated the antiinflammatorymechanismof heparin.Heparin mainly inhibits HMGB1–lipopolysaccharide